Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have received a consensus rating of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $34.38.

Several equities analysts have issued reports on VIR shares. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, March 15th. JPMorgan Chase & Co. upped their price objective on shares of Vir Biotechnology from $9.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, February 23rd.

Vir Biotechnology Stock Up 1.6 %

NASDAQ:VIR opened at $9.49 on Tuesday. The company has a fifty day simple moving average of $10.19 and a two-hundred day simple moving average of $9.66. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -2.07 and a beta of 0.41. Vir Biotechnology has a 52 week low of $7.72 and a 52 week high of $27.48.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.28. The business had revenue of $16.80 million during the quarter, compared to the consensus estimate of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The company’s quarterly revenue was down 66.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. On average, analysts expect that Vir Biotechnology will post -4.04 EPS for the current year.

Insider Buying and Selling

In related news, EVP Phillip Pang sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.24, for a total transaction of $34,007.04. Following the sale, the executive vice president now owns 264,679 shares in the company, valued at $2,710,312.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Vir Biotechnology news, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Phillip Pang sold 3,321 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $10.24, for a total transaction of $34,007.04. Following the transaction, the executive vice president now directly owns 264,679 shares in the company, valued at approximately $2,710,312.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 152,831 shares of company stock worth $1,525,844. 18.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP increased its stake in Vir Biotechnology by 1,975.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 207,500 shares of the company’s stock worth $1,944,000 after buying an additional 197,500 shares during the period. Barclays PLC increased its stake in Vir Biotechnology by 124.6% during the 3rd quarter. Barclays PLC now owns 412,161 shares of the company’s stock worth $3,863,000 after buying an additional 228,634 shares during the period. State of Alaska Department of Revenue grew its holdings in Vir Biotechnology by 205.5% during the 3rd quarter. State of Alaska Department of Revenue now owns 153,494 shares of the company’s stock worth $1,438,000 after acquiring an additional 103,246 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in Vir Biotechnology by 582.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 162,128 shares of the company’s stock worth $1,519,000 after acquiring an additional 138,387 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Vir Biotechnology during the 3rd quarter worth $1,098,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.